Sign In
Buy BIIB
$207.94
+1.66 (+0.80%)
At Close: Aug 07, 2026
Biogen (BIIB) Partner Eisai Seeks Nod for Lecanemab in Japan
02:18pm, Monday, 16'th Jan 2023
Biogen's (BIIB) partner Eisai files a marketing authorization application for lecanemab for treating early Alzheimer's disease in Japan.
Prothena (PRTA) Stock Gains 88.5% in 6 Months: What Lies Ahead?
07:47pm, Friday, 13'th Jan 2023 Zacks Investment Research
Prothena (PRTA) surges 88% in the last six months as investors are optimistic on its promising Alzheimer???s Disease pipeline.
Biogen Inc. (BIIB) Outpaces Stock Market Gains: What You Should Know
11:00pm, Thursday, 12'th Jan 2023 Zacks Investment Research
Biogen Inc. (BIIB) closed at $288.08 in the latest trading session, marking a +1.07% move from the prior day.
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
11:20am, Thursday, 12'th Jan 2023 Zacks Investment Research
Sector ETF report for XBI
Biogen's (BIIB) Partner Eisai Files MAA for Lecanemab in Europe
02:38pm, Wednesday, 11'th Jan 2023 Zacks Investment Research
Biogen's (BIIB) partner Eisai files a marketing authorization application to the European Medicines Agency for lecanemab for treating early Alzheimer's disease in Europe.
Ranking The 10 Largest Biotechs By Pipeline
12:34pm, Wednesday, 11'th Jan 2023
The pipeline is the heart of all drug discovery companies, leading to all growth in the future. As such, understanding the relative strength of a pipeline by comparing to peers can lead to investment
Biogen's (BIIB) Partner Eisai Files MAA for Lecanemab in Europe
11:17am, Wednesday, 11'th Jan 2023
Biogen's (BIIB) partner Eisai files a marketing authorization application to the European Medicines Agency for lecanemab for treating early Alzheimer's disease in Europe.
1 Hot Growth Stock to Buy Now, and 1 to Avoid
10:30am, Wednesday, 11'th Jan 2023 The Motley Fool
One company is gearing up for further growth while the other stumbles over itself.
1 Hot Growth Stock to Buy Now, and 1 to Avoid
05:30am, Wednesday, 11'th Jan 2023
One company is gearing up for further growth while the other stumbles over itself.
Should You Buy Biogen Stock After Its Latest Alzheimer's Disease Drug Approval?
10:55am, Tuesday, 10'th Jan 2023 The Motley Fool
There's more to the story with Biogen after receiving good news for Leqembi.
Should You Buy Biogen Stock After Its Latest Alzheimer's Disease Drug Approval?
05:55am, Tuesday, 10'th Jan 2023
There's more to the story with Biogen after receiving good news for Leqembi.
Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know
11:15pm, Monday, 09'th Jan 2023 Zacks Investment Research
Biogen Inc. (BIIB) closed at $274.72 in the latest trading session, marking a -1.62% move from the prior day.
Biogen Inc. (BIIB) 41st Annual J.P. Morgan Healthcare Conference (Transcript)
05:30pm, Monday, 09'th Jan 2023
Biogen Inc. (NASDAQ:BIIB ) 41st Annual J.P. Morgan Healthcare Conference Call January 9, 2023 2:15 PM ET Company Participants Chris Viehbacher - CEO Conference Call Participants Chris Schott - J.P.
Biogen (BIIB), Eisai's Lecanemab Gets FDA Nod for Alzheimer's
03:04pm, Monday, 09'th Jan 2023 Zacks Investment Research
FDA approves Biogen (BIIB) and Eisai's lecanemab on an accelerated basis. Eisai filed a supplemental biologics license application (sBLA) to the FDA to get a traditional approval for Leqembi.
‘There is a lot that's underestimated at Biogen': CEO Viehbacher
11:35am, Monday, 09'th Jan 2023
Shares of Biogen Inc (NASDAQ: BIIB) have gained nearly 45% since late September but CEO Christopher Viehbacher says there's still “a lot that's underestimated” at Biogen. Highlights from CEO's
